Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers

被引：12

作者：

Russano, Marco ^{[1
]}

La Cava, Giulia ^{[1
]}

Cortellini, Alessio ^{[1
]}

Citarella, Fabrizio ^{[1
]}

Galletti, Alessandro ^{[2
]}

Di Fazio, Giuseppina Rita ^{[1
]}

Santo, Valentina ^{[1
]}

Brunetti, Leonardo ^{[1
]}

Vendittelli, Alessia ^{[1
]}

Fioroni, Iacopo ^{[1
]}

Pantano, Francesco ^{[1
]}

Tonini, Giuseppe ^{[1
]}

Vincenzi, Bruno ^{[1
]}

机构：

[1] Campus Biomed Univ Rome, Dept Med Oncol, Via Alvaro Portillo 21, I-00128 Rome, Italy

[2] San Camillo Forlanini Hosp, Div Med Oncol, I-00152 Rome, Italy

来源：

CURRENT ONCOLOGY | 2023年 / 30卷 / 02期

关键词：

immunotherapy; non-small cell lung cancer; immune checkpoint inhibitors; PD-1; PD-L1; antibodies; combination strategies; biomarkers; tissue biomarkers; liquid biopsy; IMMUNE CHECKPOINT INHIBITORS; PD-L1; EXPRESSION; NSCLC PATIENTS; OPEN-LABEL; CHEMOTHERAPY CHEMO; 1ST-LINE NIVOLUMAB; ADVERSE EVENTS; CHECKMATE; 9LA; PATIENTS PTS; PHASE-III;

D O I：

10.3390/curroncol30020181

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and improved patients' prognosis. Immune checkpoint inhibitors have quickly become standard frontline treatment for metastatic non-oncogene addicted disease, either as a single agent or in combination strategies. However, only a few patients have long-term benefits, and most of them do not respond or develop progressive disease during treatment. Thus, the identification of reliable predictive and prognostic biomarkers remains crucial for patient selection and guiding therapeutic choices. In this review, we provide an overview of the current strategies, highlighting the main clinical challenges and novel potential biomarkers.

引用

页码：2366 / 2387

页数：22

共 50 条

[41] Effects of antibiotic use during immunotherapy in metastatic non-small cell lung cancer
Galli, G.
Poggi, M.
Fuca, G.
Imbimbo, M.
Proto, C.
Signorelli, D.
Vitali, M.
Zilembo, N.
Ganzinelli, M.
de Braud, F.
Garassino, M. C.
Lo Russo, G.
ANNALS OF ONCOLOGY, 2018, 29
[42] Perioperative Immunotherapy in Non-Small Cell Lung Cancer
Jenny O’Brien
J. Nicholas Bodor
Current Treatment Options in Oncology, 2023, 24 : 1790 - 1801
[43] Principles of Immunotherapy in Non-Small Cell Lung Cancer
Hsu, Melinda L.
Naidoo, Jarushka
THORACIC SURGERY CLINICS, 2020, 30 (02) : 187 - +
[44] Combination Immunotherapy in Non-small Cell Lung Cancer
Melina E. Marmarelis
Charu Aggarwal
Current Oncology Reports, 2018, 20
[45] Combined immunotherapy for non-small cell lung cancer
Shiraishi, Yoshimasa
ANNALS OF ONCOLOGY, 2022, 33 : S416 - S416
[46] Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer
Sanber, Khaled
Rosner, Samuel
Forde, Patrick M.
Marrone, Kristen A.
BIODRUGS, 2023, 37 (06) : 775 - 791
[47] Immunotherapy in the treatment of non-small cell lung cancer
Sundar, Raghav
Soong, Richie
Cho, Byoung-Chul
Brahmer, Julie R.
Soo, Ross A.
LUNG CANCER, 2014, 85 (02) : 101 - 109
[48] Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer
Khaled Sanber
Samuel Rosner
Patrick M. Forde
Kristen A. Marrone
BioDrugs, 2023, 37 : 775 - 791
[49] Non-small cell lung cancer in the era of immunotherapy
Huang, Quillan
Kemnade, Jan
Cornwell, Loraine
Kheradmand, Farrah
Sabichi, Anita L.
Das, Devika
SEMINARS IN ONCOLOGY, 2022, 49 (3-4) : 337 - 343
[50] Immunotherapy in Advanced Non-Small Cell Lung Cancer
Huang, Joy
Reckamp, Karen L.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 41 (03) : 400 - 408

← 1 2 3 4 5 →